Ryan, Joanne, Stanczyk, Frank Z., Dennerstein, Lorraine, Mack, Wendy J., Clark, Margaret S., Szoeke, Cassandra, Kildea, Daniel, Henderson, Victor W.

Gonadal hormones may influence cognitive function. Postmenopausal midlife women in the population-based Melbourne Women’s Midlife Health Project cohort were administered a comprehensive battery of neuropsychological tests on two occasions 2 years apart. Participants (n = 148, mean age 60 years) had undergone natural menopause and were not using hormone therapy. Estrone, total and free estradiol, […]

Egan, Kelly R., Gleason, Carey E.

Background: The cognitive effects of postmenopausal hormone therapy (HT) have been studied extensively, but little is known about the relationship between premenopausal hormone use and cognition. Hormonal contraceptive use vs. nonuse may be a potential factor influencing cognitive processes in midlife. The aim of this study is to explore the effect of modification of hormone […]

Silverman, Daniel H. S., Geist, Cheri L., Kenna, Heather A., Williams, Katherine, Wroolie, Tonita, Powers, Bevin, Brooks, John, Rasgon, Natalie L.

Differential cerebral metabolic effects of various hormone therapy formulations, and their associations with cognitive status, remain to be established. The principal aim of the current study was to assess relationships between regional cerebral metabolism and estrogen-based hormone therapies. Postmenopausal women (n=53) at elevated risk for Alzheimer’s disease (AD) were on estrogen-containing hormone therapy for at […]

Wroolie, T. E., Kenna, H. A., Williams, K. E., Powers, B. N., Holcomb, M., Lazzeroni, L., Rasgon, N. L.

Background: To determine the effects of memantine on cognition in a normal population of postmenopausal women with putative risk factors for Alzheimer’s disease (AD) using a built-in control for the genetic risk factor for AD (apoE-epsilon4 status).; Methods: A prospective, open-label, 6-month pilot medication trial with memantine and follow-up after discontinuance conducted at the Center […]

Manson, JoAnn E., Chlebowski, Rowan T., Stefanick, Marcia L., Aragaki, Aaron K., Rossouw, Jacques E., Prentice, Ross L., Anderson, Garnet, Howard, Barbara V., Thomson, Cynthia A., LaCroix, Andrea Z., Wactawski-Wende, Jean, Jackson, Rebecca D., Limacher, Marian, Margolis, Karen L., Wassertheil-Smoller, Sylvia, Beresford, Shirley A., Cauley, Jane A., Eaton, Charles B., Gass, Margery, Hsia, Judith, Johnson, Karen C., Kooperberg, Charles, Kuller, Lewis H., Lewis, Cora E., Liu, Simin, Martin, Lisa W., Ockene, Judith K., O’Sullivan, Mary Jo, Powell, Lynda H., Simon, Michael S., Van Horn, Linda, Vitolins, Mara Z., Wallace, Robert B.

Importance: Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention.; Objective: To report a comprehensive, integrated overview of findings from the 2 Women’s Health Initiative (WHI) hormone therapy trials with extended postintervention follow-up.; Design, Setting, and Participants: A total of 27,347 postmenopausal women aged 50 […]

Jacobs, Emily G., Kroenke, Candyce, Lin, Jue, Epel, Elissa S., Kenna, Heather A., Blackburn, Elizabeth H., Rasgon, Natalie L.

Apolipoprotein-ε4 (APOE-ε4) is a major genetic risk factor for cognitive decline, Alzheimer’s disease (AD) and early mortality. An accelerated rate of biological aging could contribute to this increased risk. Here, we determined whether APOE-ε4 status impacts leukocyte telomere length (TL) and the rate of cellular senescence in healthy mid-life women and, further, whether hormone replacement […]